Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.

Key PointsPharmaceutical outfit Johnson & Johnson recently reported solid overall Q3 numbers with one alarming red flag.

Read original article